In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinumresistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.
Introduction
Platinum resistance is associated with a poor prognosis for women with ovarian cancer. The use of traditional cytotoxic chemotherapy has yielded disappointing results, with reported median progression-free survival (PFS) of 3-4 months and median overall survival (OS) of about 12 months in most phase III trials [1] . As combination chemotherapy has shown no benefit over single-agent chemotherapy, monotherapy has been the standard for platinum-resistant ovarian cancer (PROC) [2] .
Angiogenesis represents an essential process in oncogenesis and tumour growth in ovarian cancer. An important angiogenic mediator is vascular endothelial growth factor (VEGF), which is produced in excess in advanced ovarian cancer and has been associated with disease progression (PD), ascites formation and poor prognosis [3] [4] [5] [6] . The anti-VEGF monoclonal antibody bevacizumab prolongs PFS when added to chemotherapy in the front-line setting [7, 8] and in platinum-sensitive disease [9, 10] . In addition, the open-label randomized phase III AURELIA trial in PROC demonstrated that adding bevacizumab to single-agent chemotherapy significantly improved the primary endpoint of PFS [hazard ratio (HR) ¼ 0.48; 95% confidence interval (CI) 0.38-0.60; P < 0.001] [11] . Median PFS was 6.7 months with bevacizumab plus chemotherapy versus 3.4 months with chemotherapy alone. Objective response rate (secondary endpoint) was also significantly improved with bevacizumab (30.9% versus 12.6%, respectively; P < 0.001). Importantly for this population, significantly more patients receiving bevacizumab plus chemotherapy than chemotherapy alone achieved a 15% improvement in patient-reported abdominal/gastrointestinal symptoms at week 8/9 [12] .
In the AURELIA trial, there was no significant difference in OS at the final analysis [HR 0.85 (95% CI 0.85-1.08); P ¼ 0.174; median 16.6 months with bevacizumab plus chemotherapy versus 13.3 months with chemotherapy alone]. AURELIA was not powered to demonstrate an OS benefit with the addition of bevacizumab to chemotherapy and optional crossover to bevacizumab after PD was allowed in patients randomized to chemotherapy alone. Therefore, no firm conclusions can be made about the impact of bevacizumab on OS in this trial. The potential discrepancy between PFS and OS results, which has been observed in several trials of anti-angiogenic therapies in various tumour types [13] [14] [15] , raises questions about the confounding effect of crossover from the control arm to antiangiogenic therapy after PD. This may lead to speculation that use of anti-angiogenic agents at the time of PD following standard therapy (sequential use) may be equally effective and potentially less toxic than upfront combination treatment with chemotherapy and anti-angiogenic therapy. This is particularly relevant for bevacizumab in ovarian cancer, as this agent has proven efficacy as monotherapy in patients with PROC [16, 17] . However, a possible limitation of the sequential strategy is the lost opportunity to use anti-angiogenic therapy in patients who are unfit to undergo active anti-tumour therapy at the time of PD following chemotherapy for PROC, or who develop conditions such as bowel obstruction that could preclude bevacizumab administration. We report exploratory analyses aiming to determine the impact on outcomes in PROC of crossover and timing of bevacizumab initiation.
Patients and methods

Study design
The design and methods of the AURELIA trial have been published previously [11, 12] Chemotherapy and bevacizumab were continued until PD, unacceptable toxicity or consent withdrawal. Patients randomized to chemotherapy alone were allowed to receive single-agent bevacizumab 15 mg/kg q3w on clear evidence of PD after careful individual riskbenefit assessment by the investigator and providing patients remained eligible for AURELIA. This was particularly relevant for exclusion criteria, which may have developed during the course of study treatment: bowel obstruction (including subocclusive disease) related to underlying disease, abdominal fistula, gastrointestinal perforation, intraabdominal abscess, evidence of rectosigmoid involvement, bowel involvement on computed tomography, clinical symptoms of bowel obstruction, radiotherapy to the pelvis or abdomen, surgery (including open biopsy) within 4 weeks before starting bevacizumab (within 24 h for minor surgical procedures) or anticipated need for major surgery during bevacizumab treatment. Patients also had to have an Eastern Cooperative Oncology Group (ECOG) performance status of 2. The study was approved by national and/or participating-institution independent ethics committees.
To investigate the possible impact of the timing of bevacizumab therapy in relation to chemotherapy administration, we carried out an exploratory analysis to compare outcomes in three subgroups of patients treated in the AURELIA trial.
Statistical analysis
In this exploratory analysis, patients were classified into one of three subgroups: patients who received upfront bevacizumab concurrently with chemotherapy; patients who received bevacizumab after PD on single-agent chemotherapy; and patients who never received bevacizumab. To explore patient and disease characteristics associated with receiving bevacizumab after PD, we compared proportions of patients in each subgroup with known prognostic factors for OS at baseline and at PD using v 2 and Fisher's exact tests. It was considered likely that patients initially randomized to chemotherapy who never received bevacizumab after PD had a worse prognosis than those who received optional bevacizumab after PD, explaining the lack of further salvage treatment. To test this hypothesis, we used a previously developed prognostic nomogram for OS [18] to compute a risk score for each patient based on the presence or absence of the following adverse prognostic features at randomization: ECOG performance status 1 or 2; ascites; cancer antigen-125 100 IU/ml; platinum-free interval <3 months; measurable tumour <5 or5 cm; and primary platinum resistance. We then categorized patients within each of the three subgroups as having either a 'good' or a 'poor' prognosis based on the median distribution of the risk score. OS differences between the three subgroups and, within those, between subgroups of 'good-prognosis' and 'poor-prognosis' patients, were examined using Cox regression analyses.
We also explored potential differences in the incidences of typical bevacizumab toxicities. In patients randomized to upfront bevacizumab and chemotherapy combination therapy, only adverse events (AEs) occurring between randomization and PD were considered. In patients initially randomized to chemotherapy alone who subsequently crossed over to bevacizumab after PD, only AEs occurring after PD were considered. This potentially introduced a bias because AEs occurring after PD but before initiation of bevacizumab would be attributed to bevacizumab, but was the best estimation possible with the available information.
The data cut-off for all analyses was 25 January 2013. Analyses were carried out using Stata (version 13.1; StataCorp LLC, College Station, TX) or SAS (version 9.3; SAS Institute Inc., Cary, NC).
Results
Patient population
Of the 361 patients randomly assigned in AURELIA, 110 received upfront chemotherapy alone but did not cross over to receive bevacizumab (group 1), 72 received upfront chemotherapy alone and crossed over to receive bevacizumab after PD (group 2) and 179 were randomly assigned to receive upfront chemotherapy combined with bevacizumab (group 3) (Figure 1) . The reasons for group 1 patients not receiving bevacizumab after stopping study treatment were not captured in the AURELIA database. After closer interrogation of the database, the reason remained unknown in 56 patients (51%). In the remaining patients, the potential reasons were: no PD (N ¼ 8, 7%), death within 12 weeks of PD (N ¼ 37, 34%), ECOG performance status 2 (N ¼ 7, 7%), and grade 3 AEs (N ¼ 2, 2%; bleeding and hypertension). There were no differences in baseline characteristics or prognostic classification between groups 1 and 2 ( Table 1) . The distribution of patients between groups 1, 2 and 3 according to factors contributing to the nomogram is shown in supplementary Table S1 , available at Annals of Oncology online.
Overall survival
Compared with patients never receiving bevacizumab (group 1), the HR for OS was 0.68 (95% CI 0.52-0.90; P ¼ 0.01) in patients receiving bevacizumab upfront (group 3) and 0.60 (95% CI 0.43-0.86; P ¼ 0.01) in patients receiving bevacizumab after PD (group 2) representing reductions of 32% and 40%, respectively, in the risk of death. When groups 2 and 3 were combined, a 34% reduction in the risk of death was observed in patients receiving bevacizumab either upfront or after PD compared with no bevacizumab therapy (group 1) (HR 0.66; 95% CI 0.51-0.85; P ¼ 0.001; Figure 2 ). When compared with no bevacizumab therapy (group 1), patients classified as 'poor prognosis' derived an OS benefit from bevacizumab upfront (group 3: HR 0.58) or after PD (group 2: HR 0.63) (Figure 3 ). Among patients classified as 'good prognosis', a similar benefit was suggested for patients receiving bevacizumab at PD (group 2: HR 0.64) but the benefit for upfront bevacizumab was numerically smaller (group 3: HR 0.91). These results, however, should be viewed cautiously due to the limited power of these subgroup analyses and 95% CIs crossing 1 in all comparisons except the poor-prognosis subgroup of group 3 versus group 1.
Safety
The median duration of bevacizumab therapy was 6.5 [interquartile range (IQR) 5.0-9.7] months in patients receiving bevacizumab after PD (group 2) and 5.1 (IQR 1.9-8.4) months in those receiving combined bevacizumab and chemotherapy (group 3). Grade 3 AEs were generally infrequent, the most common being hypertension (7% of patients receiving combined bevacizumab and chemotherapy versus 1% receiving bevacizumab after PD on chemotherapy alone; P ¼ 0.25; Table 2 ). Corresponding proportions for grade 2 hypertension were 17% versus 11%, respectively (P ¼ 0.86).
Discussion
We studied differences in outcome and tolerability associated with the use or not of bevacizumab in PROC, as well as outcomes according to the timing of administration of this agent (after PD or concurrently with chemotherapy). We had two reasons for conducting these exploratory analyses: firstly, to explore the confounding effect on OS of crossover to bevacizumab among patients randomized to the control arm of AURELIA; and secondly, to provide some insight on the optimal use of bevacizumab in PROC in everyday practice. Our analysis showed a significant OS benefit from the use of bevacizumab compared with patients who never received this treatment. The benefit was not dependent on the timing of bevacizumab initiation (concurrently with chemotherapy versus after PD on single-agent chemotherapy). Several limitations of these analyses are recognized. This was a post hoc analysis with limited statistical power. More importantly, non-randomized comparison is not the ideal method for obtaining unbiased estimates of treatment effects and thus our analysis remains hypothesis-generating to stimulate future research. For example, bevacizumab administration at relapse may have introduced a bias for better prognosis. Reasons for not administering bevacizumab at PD were not captured in AURELIA and consequently we were able to identify potential reasons for this practice in only half of the patients. Reassuringly, we found no imbalances in baseline characteristics with known prognostic relevance across the three groups studied. Nevertheless, the existence of imbalances in unknown yet important prognostic factors cannot be excluded. The proportion of patients who received no treatment after PD is unknown, while detailed information regarding therapy after PD was lacking (except for bevacizumab). It should be emphasized, however, that no comparison between available chemotherapeutic agents or combinations has shown prolongation of OS in patients with PROC [1, 19] . Therefore, it is unlikely that imbalances in the use of post-PD therapies (other than bevacizumab) would have confounded our findings. Finally, eight patients who were alive without PD at the end of study treatment were included in group 1 (patients randomized to chemotherapy alone who did not receive bevacizumab). The inclusion of these patients with continued benefit from chemotherapy introduces some bias in the analysis but if anything, inclusion of these patients in group 1 could be expected to lead to overestimation of OS in this subgroup, which ultimately had the worst OS.
There are preclinical data supporting both bevacizumab strategies explored in this analysis. Combining bevacizumab and chemotherapy may yield maximum benefit because of their reported synergistic effects [20] . However, chemotherapy administration may show anti-angiogenic effects [21] and stabilize tumour vasculature, increasing susceptibility to the effects of subsequent VEGF-blocking therapy [22] . If these preclinical models translate to the clinical setting, bevacizumab after PD on chemotherapy alone may also be beneficial. This notion is supported by the considerable efficacy of single-agent bevacizumab in PROC [16, 17] . As AURELIA was not designed to compare these two bevacizumab strategies prospectively, it is impossible to draw definitive conclusions from AURELIA regarding the optimal timing of bevacizumab administration. Nevertheless, it should be emphasized that 60% of patients in the chemotherapy-alone arm never received bevacizumab. Although the reasons for this were not recorded, a detailed search of the database revealed that death within 12 weeks of PD, deterioration in ECOG performance status, and relevant AEs may have precluded the use of bevacizumab after PD in at least 46 patients. This observation supports the use of bevacizumab concurrently with chemotherapy in PROC at the earliest opportunity to maximize the number of patients having the opportunity to receive anti-angiogenic therapy.
Safety considerations may influence treatment decisions between two equally effective therapeutic strategies. In this analysis, toxicities associated with bevacizumab were similar regardless of the timing of bevacizumab administration and were generally infrequent. The incidence of grade 3 hypertension was numerically lower when bevacizumab was administered after PD on chemotherapy alone. However, this difference did not reach statistical significance, perhaps because of the relatively small number of patients in this analysis, or perhaps because of potential overestimation of events in the sequential arm because all AEs occurring after PD were considered, regardless of the time of onset in relation to bevacizumab initiation. Nevertheless, the incidence of grade 3 hypertension was low in both subgroups, underlining the good tolerability of bevacizumab in this population.
In conclusion, the lack of OS benefit from the addition of bevacizumab to chemotherapy in the AURELIA trial may be partially attributed to the confounding effect of bevacizumab administration after PD in the control arm. Early treatment of PROC with bevacizumab plus chemotherapy combination therapy ensures that most patients with this disease can benefit from antiangiogenic therapy. However, if this strategy has not been adopted, the use of bevacizumab after PD on chemotherapy alone for PROC may be beneficial.
